Furthermore, a retrospective international multicenter study that evaluated the effects of SGLT2 inhibitors in patients with biopsy-proven glomerulonephritis reported that 31 % of patients had insufficient reduction in proteinuria [25]. The gene discussed is SLC5A2; the disease is glomerulonephritis.